Sustained pain reduction, improved mobility, and strong safety profile position Allocetra™ as a potential game-changer for aging patients
Enlivex Therapeutics Ltd., a Nasdaq-listed clinical-stage immunotherapy company, has announced compelling six-month efficacy results from the Phase IIa portion of its multinational Phase I/II Allocetra™ trial for moderate to severe knee osteoarthritis (OA). The latest findings reinforce earlier three-month data and highlight a clear responder population among adults aged 60 and older, suggesting a meaningful therapeutic breakthrough in a field long dominated by pain management rather than disease-modifying solutions.
The study demonstrated that Allocetra™—a macrophage reprogramming treatment designed to modulate inflammation—produced substantial and durable reductions in pain while improving physical function. In patients aged 60+, the therapy showed a statistically significant improvement at three months, with a 99% greater reduction in composite pain and function scores compared to placebo. At six months, this benefit persisted, with an 80% improvement over placebo in patients aged 61 and older. These results underscore not only efficacy, but durability—an especially notable outcome given that a single treatment cycle generated at least half a year of sustained clinical benefit.
Equally important, Allocetra™ maintained a favorable safety profile throughout the six-month follow-up, mirroring earlier findings and reinforcing its potential as a viable long-term therapy. As knee osteoarthritis continues to rise due to aging and obesity, experts view innovative immune-modulating strategies as essential. Professor Philip Conaghan, an international leader in OA research, praised the study’s promise, emphasizing the growing need for effective treatments that target inflammatory pathways.
Enlivex leadership echoed this optimism. CEO Dr. Oren Hershkovitz highlighted both the therapeutic impact and commercial potential, while CMO Dr. Einat Galamidi confirmed plans to launch a Phase IIb trial in early 2026. If future results continue this trajectory, Allocetra™ could represent a transformative new option for millions suffering from age-related knee osteoarthritis.
You might like this article:Powering the Next Era of Public Sector AI: Amazon’s Historic $50 Billion AWS Investment
